To enhance the clinical translational value of DDR1 as a therapeutic target for HNSCC, we employed a highly selective DDR1 inhibitor, 7rh, in combination with carbon ion therapy, aiming to observe its radiosensitization effect on HNSCC. This evidence concerns the gene DDR1 and head and neck squamous cell carcinoma.